com

How to Overcome Your Device Dependency and Manage a Successful Digital Detox

Getting outside – without your phone – is one way to disconnect.




com

Yellowstone star’s comments on last episode will worry long-time fans

Viewers were left stunned by ‘savage’ exit of character in first episode of new season




com

Gender Neutral Blood Donation Comes With Sting In Its Tail

The blanket ban on blood donation by gay men, and bisexual men and transgender women who have sex with men (GBT people), is one step closer to being lifted. The ...

The post Gender Neutral Blood Donation Comes With Sting In Its Tail appeared first on Star Observer.




com

Are Libra and Capricorn Compatible? Exploring Their Relationship Dynamic

Libra and Capricorn compatibility blends charm and ambition. Discover how this air-earth duo balances romance and practicality in love, friendship, and relationships.




com

cancer and aquarius compatibility

Discover if Cancer and Aquarius can make a love match! Learn about their compatibility, strengths, challenges, and what to expect in a relationship.




com

How Compatible Are Libra and Aquarius? Relationship Insights

Discover the compatibility between Libra and Aquarius in love, friendship, and more. Explore their strengths, challenges, and what makes this zodiac pairing unique.




com

Nintendo Switch 2: Everything we know about the coming release

As the world turns, so do the console generations. The Nintendo Switch is over seven years old, so it’s due for a refresh. Nintendo Switch 2 rumors have been swirling for years, but now they are really heating up. A sequel to Nintendo's most successful home console ever is coming and it’s likely coming sooner rather than later.

Will it be a straight up sequel to the Switch with updated specs while retaining the same hybrid functionality or will Nintendo get weird with it? Will it even be called the Switch 2, or will the company go with something like the Super Switch or even the New Nintendo Switch? You can never tell with Nintendo. Heck, maybe it’ll call the thing the Switch U.

In any event, recent weeks have brought feverish speculation regarding all aspects of the forthcoming gaming console. It’s important to note, however, that very little information has been confirmed by Nintendo. The company operates on its own timetable. With that said, here are all of the rumors that are most likely to come true, given industry analysis.

As previously mentioned, Nintendo marches to the beat of its own drum. We don’t exactly know when it’ll hold an event to reveal the console. It likely won't be in 2024, as the tech year is winding down and it's rare to get announcements of new harder in late November and December. 

Even Nintendo has trouble keeping the lid on a major console release, so we could learn something before the official reveal. There are parts that have to be sourced and shipments that have to be made. A senior analyst at MST Financial noted a spike in production equipment spending by Nintendo assembler Hosiden.

Once again, this is more or less a mystery. We aren’t totally in the dark, but it’s mostly rumor and speculation. One thing we know for sure is that Nintendo will announce the Nintendo Switch 2 (or whatever it chooses to call it) by March 2025, as the company confirmed back in May. Some are saying there will be a March release date, which makes sense given the OG Switch came out on March 17, 2017. However, other reports put the console’s release window later in 2025.

We can infer a lot from the announcement date. If the console is announced this year, March would be a safe bet, given that the original Switch was officially confirmed in October of 2016. However, the console likely won't be announced until next year, at this point, so expect a late 2025 release. 

Nintendo has a weird track record here. The baffling Wii U followed the massive success of the Wii. The Wii itself followed the more traditional GameCube. In other words, it’s possible it’ll be something out of left field and not exactly a true sequel to the Switch. However, this is unlikely this time around. As much as I would love to see wacky VR glasses or a completely bonkers console concept, all points indicate a more traditional approach.

Developers have already seen the hardware, though in a much earlier form, and it seems to be a regular old console. While Nintendo hasn't confirmed hybrid functionality, it’d be a weird omission given the absolute financial firestorm of the Switch. We’ve also heard rumors of a Mini-LED display, which would track for a hybrid console. It’s highly likely this will be a straight-up Switch 2, or something like it, calling to mind the Super Nintendo.

To that end, recent rumors suggest a design that recalls the original Switch. According to reporting by VGC, photos of the console have appeared online and they show an 8-inch screen and magnetic Joy-Con controllers. There looks to be SL/SR buttons and front-facing player LEDs on these controllers. 

If it’s a sequel to the Switch, the next question has to be about backwards compatibility. The Switch’s library is absolutely massive, and continues to grow, so gamers would be rightfully peeved if they couldn’t play Tears of the Kingdom on their new next-gen console. There’s good news on this front.

The company has officially announced in a recent earnings report that the console will be fully backwards compatible. It will also feature access to Nintendo Online, so users will be able to play all of those old retro titles. 

The rumors regarding specs are all over the place, so it’s tough to pin down. We know one thing for sure: It’ll be more powerful than the ancient Switch hardware, which was already antiquated back in 2017. One analyst allegedly got a hold of a spec sheet from the Korean United Daily News that said the Switch 2 would boast an eight-core Cortex-A78AE processor, 8GB of RAM, and 64GB of internal eMMC storage. This tracks for me, as these specs are about as underpowered in 2024 as the original Switch was in 2017. However, some reports do indicate that the console would include 12GB of RAM. 

Another source suggests that the eight-core CPU will be packaged inside an NVIDIA-produced Tegra239 SoC (system on a chip). Given the current Switch runs on an NVIDIA chip, that makes a lot of sense. The CPU will be more powerful, but it's the Switch 2's new GPU that will be a major differentiator. It's all-but-confirmed that the Switch 2 will support DLSS, NVIDIA's "deep learning supersampling" upscaling tech, which would allow the console to render games at a low resolution internally while outputting a high-resolution image. (Fun fact: We actually wrote about how perfect DLSS was for the Nintendo Switch 2 when the technology was announced alongside the RTX 20 series back in 2018.)

There are still questions about the Switch 2 and DLSS: Will the system support newer DLSS features like frame generation? Will existing games be automatically tidied up by NVIDIA's algorithm? Regardless of the exact implementation, DLSS upscaling will be a huge leap over the rudimentary techniques available to Nintendo Switch developers.

As for the display, there are many conflicting rumors. Early reports from solid sources suggested the Switch 2 would have an 8-inch display LCD display, but there have also been rumors about an 7-inch display with a 120Hz refresh rate. Some analysts have suggested this would be an OLED screen, while others have said it would be a Mini-LED display. A Mini-LED display is basically an LCD display that has a backlight made of (surprise!) mini-LEDs rather than edge lighting. This allows for local dimming, making the blacks more black. I’m hedging my bets here. I think it’ll be a standard LCD, to cut costs, with an OLED or Mini-LED model coming later down the line. However, Mini-LED screens are slightly cheaper than OLED displays, so that’s certainly a possibility at launch.

As for resolution, recent reporting suggests that the console will output 1080p in handheld and 4K when docked. That's much better than the OG Switch. 

We don't have too much information regarding price but we do have plenty of history to work with. The original Nintendo Switch launched at $300, which is pretty much the "magic number" when it comes to Nintendo console releases in recent years. The Wii U also came in at $300. 

However, there are plenty of rumors circulating that Nintendo could be upping the asking price for the Switch 2. Numerous outlets have reported it'll be $400, or potentially even more expensive. However, the same analysts who say the console will be $400 were also fairly certain it would be out by the end of 2024 and, well, it looks like that ain't happening. 

Dipping back into history, there is some precedence for a price uptick. The GameCube was $200 and the Wii was $250. The Wii U and Switch increased to $300 and, well, numbers like to go up. A $400 price tag would make it nearly as expensive as a PS5 and Xbox Series X. That would also put it at the same price as the 256GB LCD Steam Deck. 

Nope! But it’s certainly been a long time since we’ve gotten a proper 3D Mario adventure, right? That would be one heck of a system seller. Other than that, your guess is as good as mine. Past as prologue, we can expect something from Ubisoft and an off-the-wall title like 1-2-Switch

If there’s a gimmick or hook involved with the console, we’ll also get a game that takes advantage of that. A dual release of Metroid Prime 4, just like Breath of the Wild and Twilight Princess before that, is also a possibility.


That's everything we know about the Nintendo Switch 2 today. We'll update this article with rumors we trust and with information we gather directly from sources. Any changes made to the article after its initial publishing will be listed below.

Update, November 11, 2024, 9:00 AM ET: This story has been updated with details about the Switch 2's backwards compatibility as well as more details about the current expected announcement and release timeline.

This article originally appeared on Engadget at https://www.engadget.com/gaming/nintendo/nintendo-switch-2-everything-we-know-about-the-coming-release-110023903.html?src=rss




com

PS5 exclusive Stellar Blade is coming to PC

This year's action RPG Stellar Blade has been a solid win for Sony as a PlayStation 5 exclusive. Developer Shift Up revealed in a recent quarterly earnings report that sales "have remained steady even as the initial surge has calmed" following its spring launch. But there may be a second boost coming for the game, because the studio is planning a PC port of Stellar Blade some time next year.

"Given recent trends like Steam’s growing presence in the AAA games market and the global success of Black Myth: Wukong, we are expecting the PC version to perform even better than the console version," the Korean company said when asked about their PC plans during the presentation.

The title referenced, Black Myth: Wukong, was able to set a new record for concurrent players in a single-player game on Steam when it launched on the platform in August. That's a lofty goal for any game to reach, so we'll have to see how successful Shift Up can be in reaching an international audience on PC.

This article originally appeared on Engadget at https://www.engadget.com/gaming/ps5-exclusive-stellar-blade-is-coming-to-pc-231625263.html?src=rss




com

Le Carnet de Karine: Sylvain Croteau combat la violence dans le sport

Amoureux du sport, Sylvain Croteau a décidé de consacrer sa carrière, depuis 10 ans, à prévenir et à contrer la violence et les abus dans ce monde.




com

Des chercheurs ont découvert comment diminuer les chances d'être attaqué par un requin en surf

Le grand requin blanc attaque souvent ses proies par en dessous, confondant parfois la silhouette d’un surfeur avec celle d’un phoque.




com

Temple de la renommée: Jeremy Roenick raconte comment Doug Wilson lui a sauvé la vie

Jeremy Roenick nous a offert le moment le plus touchant de l’intronisation des membres de la cuvée 2024 du Temple de la renommée du hockey.




com

Le plus grand hockeyeur au monde ne devrait pas patiner comme ça, surtout à 16 ans: «Il est une énigme»

Un défenseur bélarusse au potentiel incalculable réalise bien malgré lui les défis quotidiens qui accompagnent son physique hors-norme.




com

Surfwear company cuts 40 jobs

THE soap opera continues for SurfStitch as the surfwear brand sheds 40 jobs in a bid to return to profit.




com

Indian capital plans drone flights to combat smog crisis

New Delhi (AFP) Nov 8, 2024
India's capital unveiled plans Friday to fly special drones to clear pollution from its smog-choked skies - a plan derided by experts as another "band-aid" solution to a public health crisis. New Delhi and the surrounding metropolitan area, home to more than 30 million people, consistently tops world rankings for air pollution in winter. The smog is blamed for thousands of premature de




com

Commission Parent 2.0: une idée bonne mais risquée

Depuis quelques années, et avec une plus grande intensité au cours des derniers jours, plusieurs proposent la création d’une commission Parent 2.0.




com

Administration Trump: un «faucon» anti-Chine comme secrétaire d'État, une «tueuse de chiens» à la Sécurité intérieure

Un «faucon» anti-Chine à la diplomatie, une gouverneure «tueuse de chiens» à la sécurité intérieure.




com

Le comptable disparu de Saint-Jean-sur-Richelieu aurait été assassiné

Un mois après la mystérieuse disparition d’un comptable sans histoire de Saint-Jean-sur-Richelieu, le corps de l’homme de 68 ans a été retrouvé.




com

Influenceur en cryptomonnaie enlevé dans le Vieux-Montréal: le corps décomposé de Kevin Mirshahi retrouvé

Le corps ligoté en état de décomposition retrouvé le 30 octobre dans l’un des parcs les plus achalandés de Montréal est celui de Kevin Mirshahi.




com

Un citoyen souverain qui se présente comme un «gentilhomme de la paix» encore coupable d’entrave

Amoury Lapointe a résisté à son arrestation lors d’une intervention de routine à laquelle il refusait de se soumettre dans son «véhicule diplomatique»




com

Via Rail's performance has gone from bad to worse — and it's costing the company millions

Via Rail's service standards have eroded substantially over the last decade, with many more trains arriving late.




com

'Christmas creep' is here as the retail season starts early. But is it about consumerism or comfort?

If it seems like the Christmas shopping season starts earlier every year, you're not wrong. In response to growing customer demand, stores of all stripes brought out their festive collections weeks before the unofficial start of the holiday shopping season.




com

Former U.S. commerce secretary says he 'can't imagine' Trump would tax Canadian energy

Donald Trump's former commerce secretary says he 'can't imagine' the U.S. president-elect would want to tax Canadian energy, despite campaign promises about imposing a global tariff when he takes office in January.




com

Canada Post workers give 72-hour notice to strike as company warns of financial impact

The union representing Canada Post workers said it will be in a legal strike position on Friday, exactly one year after talks on a new contract began. But the union is holding back on deciding whether a job action will take place immediately.




com

Privacy commissioner launches investigation into World Anti-Doping Agency

Canada’s privacy commissioner has launched an investigation into the World Anti-Doping Agency (WADA) and “its handling of biological samples collected from athletes.”




com

Guylaine Tanguay tiendra la vedette de la mouture québécoise de la comédie musicale «Ménopause»: «J’ai besoin de me mettre en danger»

Elle tiendra la vedette de l’adaptation québécoise du succès mondial Ménopause aux côtés de Claudine Mercier, Catherine Sénart et Geneviève Charest.




com

Mieux comprendre la douleur et l’effet placebo

La découverte d’un circuit cérébral impliqué dans l’effet antidouleur des placebos pourrait permettre le développement de traitements analgésiques.




com

SEC recommends marketing approval for Dr Reddy's SPMS drug Siponimod tablets

The Subject Expert Committee (SEC), which advises the national drug regulator on approval of new drugs and clinical trials, has recommended grant of market authorisation for Dr Reddy's Laboratories' Siponimod




com

Indian health, pharma companies invited to participate in Iraq's 'Medico Expo' from Feb 5─8, 2025

The Embassy of India in Iraq has extended an invitation to Indian businesses to participate in the "Medico Expo," officially known as the Erbil International Health Exhibition. This prestigious event, set to be the




com

SEC recommends approval for MSN Laboratories' sleep disorder drug

The Subject Expert Committee (SEC), which advises the national drug regulator on matters related to approval of new drugs and medical devices and clinical trials, has recommended grant of market authorisation for




com

Indian healthcare industry to invest further in computational infrastructure for data integration in patient care

The Indian healthcare industry is looking to invest further in computational infrastructure as data integration frameworks and regulatory compliance are pivotal to ensure intelligent clinical support




com

Inter─ministerial committee calls for amendment in FSSAI Act on nutraceuticals

An inter─ministerial committee formed by the Union health ministry has recommended amendments to the Food Safety and Standards Act, 2006 and regulations on nutraceuticals and health supplements, to shift regulation of




com

WITTMANN BATTENFELD presents latest technology at Compamed

WITTMANN BATTENFELD will present the latest solutions for time and cost optimisation in the production of parts with nano structures at Compamed, booth No. F03-1 in hall 8b.




com

Accumold showcases micromoulding innovation at Compamed

Accumold, with over 40 years of experience in micromoulding technology, is set to participate at Compamed, taking place in Düsseldorf, Germany, from 11-14 November. The company will highlight its small and complex parts for medical device OEMs.




com

Syensqo to showcase portfolio of medical-grade polymers at Compamed

Syensqo, previously part of Solvay Group and a global provider of advanced performance materials and chemical solutions, is making its debut at Compamed 2024.




com

Trelleborg Medical Solutions showcases polymer-based solutions at Compamed

Trelleborg Medical Solutions showcases its comprehensive polymer-based solutions and capabilities for the medical technology and biopharmaceutical industries at Compamed 2024 in Dusseldorf from November 11 to 14, at stand F02 in hall 8A.




com

Why Election Polling Has Become Less Reliable

Election polls are increasingly vulnerable to huge mistakes




com

Let African Communities Manage Their Climate Adaptation Plans

Outside groups often offer their solutions for climate adaptation in Africa. But the best people to manage the climate crisis are the people in those communities themselves. For climate adaptation to succeed in Africa, let communities and local leaders show the way




com

The Lucy Fossil’s Extraordinary Journey to Becoming an Icon of Human Evolution

The 3.2-million-year-old human ancestor known as Lucy rose to fame through an incredible combination of circumstances




com

How Field Reimbursement Services Help Overcome Coverage Barriers and Improve Patient Outcomes

Today’s guest post comes from Kimberley Chiang, Vice President of Biopharma Commercial Solutions at CoverMyMeds

Kimberley highlghts the crucial roles of field reimbursement managers in removing access and reimbursement barriers. She then identifies the keys to successful implementation of field reimbursement services.

To learn more, register for CoverMyMeds' November 13, 2024, webinar: Specialty Therapies & Field Reimbursement Services: Driving Better Outcomes for Brands and Patients.

Read on for Kimberley’s insights.
Read more »
       




com

Orphan Drugs at 30: Will Success Become Too Expensive?

The Orphan Drug Act (ODA) turned 30 this month, demonstrating that good laws really can have an enduring impact. Amidst the celebrations, a reporter asked me a provocative question: can we afford more orphan drugs costing hundreds of thousands of dollars per year? FDA Matters answered “yes.” However, I added a caveat that should worry everyone eager for orphan drugs to succeed. When genomics and personalized medicine become successful, this will multiply the number of rare diseases and the overall cost of orphan drugs, perhaps beyond what the system can bear.




com

More Columns Coming; The Alliance for a Stronger FDA

FDA Matters appreciates your patience. New columns will be coming in June, with fresh insights into FDA and the FDA-regulated world.  Meantime, I write a weekly column in the Friday Update, published by the Alliance for a Stronger FDA. If you want to receive the Friday Update when it's published each week, you can sign […]




com

Revised APRA Bill Clears House Subcommittee

The proposed American Privacy Rights Act (APRA) has taken its first step U.S. House legislative process with several issue disagreements becoming more evident. On May 23, the U.S. House Committee on Energy and Commerce Subcommittee on Data, Innovation and Commerce approved the updated APRA, advancing the bill to full committee consideration. Just prior to the […]




com

Minnesota Becomes 18th State to Adopt Consumer Data Privacy Law

On May 24, Governor Tim Walz signed into law Minnesota’s new comprehensive data privacy law, the Minnesota Consumer Data Privacy Act (HF 4757 referenced as the MCDPA). The MCDPA goes into effect on July 31, 2025, with some exceptions for colleges and universities (who have until 2029). The MCDPA is similar to other state privacy laws, […]




com

EMA recommends approval of aflibercept biosimilars Afqlir and Opuviz

<p>On 19&nbsp;September 2024, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP)&nbsp;adopted a positive opinion,&nbsp;recommending the granting of marketing authorization&nbsp;for&nbsp;two aflibercept biosimilars:&nbsp;&nbsp;Sandoz’s Afqlir and Samsung Bioepis’s Opuviz.&nbsp;These products are biosimilars of the reference product Eylea, developed by Regeneron and Bayer.</p>




com

Bio-Thera and Gedeon Richter partner to commercialize Stelara biosimilar BAT2206

<p>In October 2024, China based Bio-Thera Solutions&nbsp;(Bio-Thera)&nbsp;and Hungary’s Gedeon Richter announced they have reached an exclusive commercialization and license agreement for BAT2206, a biosimilar candidate to&nbsp;Johnson &amp; Johnson’s Stelara (ustekinumab).</p>




com

Government 'miscommunicated' PPE stock levels to pharmacies during first COVID-19 wave, MPs told

The government implied wholesalers had more personal protective equipment in stock than was the case during the first wave of the COVID-19 pandemic, the Healthcare Distribution Association has said.




com

Prime minister vows to reimburse community pharmacy's COVID-19 costs 'as soon as possible'

Community pharmacies should be reimbursed for their additional costs during the COVID-19 pandemic “as soon as possible”, the prime minister has told The Pharmaceutical Journal.




com

New drug cuts the risk of death in bladder cancer by 30% compared with chemotherapy, study suggests

A new type of drug that targets chemotherapy directly to cancer cells reduces the risk of death from the most common type of bladder cancer by 30%, a phase III trial in the New England Journal of Medicine has suggested.




com

Pharmacy negotiators discuss patient registration with community pharmacies

Pharmacy negotiators have discussed proposals to take “a patient registration-based approach” to the community pharmacy contractual framework.




com

Boiling It Down: Conveying Complexity For Decision-makers

By Ankit Mahadevia, former CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC Drug development is complex. So is running a business. Sometimes, the work of doing both can make your head spin. In my

The post Boiling It Down: Conveying Complexity For Decision-makers appeared first on LifeSciVC.